Vanguard Fiduciary Trust’s GT Biopharma GTBP Stock Holding History

Vanguard Fiduciary Trust’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$111K	Hold	225,938	–	–	﹤0.01%	3720
2026 Q1	$92.2K	Buy	+225,938	New	+$123K	﹤0.01%	3728

Other funds holding GTBP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

OWA

Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

4WM

49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return

Alongside Austin, Texas $525M AUM

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

Vanguard Fiduciary Trust's GTBP Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its GT Biopharma (GTBP) position steady in Q2 2026 at 225,938 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #3720.

Vanguard Fiduciary Trust first reported a position in GTBP in Q1 2026 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

Vanguard Fiduciary Trust held 225,938 shares of GT Biopharma worth $111K as of Q2 2026.
Vanguard Fiduciary Trust left its GT Biopharma share count unchanged in Q2 2026.
GT Biopharma made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3720 holding.
Vanguard Fiduciary Trust first reported a position in GT Biopharma in Q1 2026 and has held it in 2 quarters since.
57 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.